ArticleJournal of oral and maxillofacial pathology : JOMFP
Evaluation of the role of salivary survivin and caspase-3 in apoptosis regulation in oral submucous fibrosis and oral squamous cell carcinoma among gutka chewers.
Article in Journal of oral and maxillofacial pathology : JOMFP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study evaluates salivary Survivin and Caspase-3 as key regulators of apoptosis across a disease spectrum-from gutka chewers without lesions to oral submucous fibrosis (OSMF) and oral squamous cell carcinoma (OSCC). Survivin, an anti-apoptotic protein, and caspase-3, the principal executioner caspase, represent crucial biomarkers of malignant transformation, especially in populations with high smokeless tobacco exposure. Materials and Methods: A cross-sectional analytical study included 92 participants divided into: controls (n = 17), gutka chewers without lesions (n = 25), OSMF (n = 25), and OSCC (n = 25). Unstimulated saliva samples were collected and analysed for Survivin and Caspase-3 using ELISA. Statistical analysis included Pearson correlation and Kruskal-Wallis. Results: Mean survivin levels demonstrated a progressive increase from healthy subjects (1.00 ± 0.73 pg/ml) to gutka chewers without lesions (2.00 ± 1.36 pg/ml), OSMF (3.50 ± 2.82 pg/ml), and OSCC (5.00 ± 3.04 pg/ml), indicating a trend towards increased anti-apoptotic activity with disease progression. In contrast, Caspase-3 levels showed a biphasic pattern, measuring 4.90 ± 4.43 ng/ml in healthy subjects, 4.50 ± 2.71 ng/ml in gutka chewers without lesions, decreasing to 3.50 ± 2.82 ng/ml in OSMF, and subsequently increasing to 5.50 ± 3.62 ng/ml in OSCC. Conclusion: Survivin demonstrated potential as a biomarker of malignant transformation in gutka-associated oral potentially malignant disorders, while the non-linear pattern of Caspase-3 highlights the complex regulatory interactions involving apoptosis suppression, hypoxic adaptation, and possible apoptosis-induced proliferation. However, both biomarkers may serve as potential indicators of disease progression, pending validation through larger multi-centre studies with longitudinal follow-up.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.